09-07-2025
- Business
- Wall Street Journal
Vie Ventures Launches to Bankroll Autoimmune-Disease Biotechs
Two veteran life-sciences investors have launched Vie Ventures, which plans to fund biotechnology startups targeting autoimmune diseases and connect them with nonprofits that might accelerate their drug development.
Vie Co-founders Luke Evnin and Dr. Steven St. Peter previously invested together with MPM Capital, now MPM BioImpact. Both also have experience with nonprofits: Evnin is chairman of the Scleroderma Research Foundation and St. Peter most recently was managing director of the T1D Fund, the venture-philanthropy arm of Breakthrough T1D, which supports Type 1 diabetes research.
